Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Shares Sold by Kennedy Capital Management LLC

Kennedy Capital Management LLC decreased its holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 2.3% in the 4th quarter, Holdings Channel reports. The institutional investor owned 1,017,666 shares of the biopharmaceutical company’s stock after selling 23,750 shares during the period. Kennedy Capital Management LLC’s holdings in Catalyst Pharmaceuticals were worth $21,239,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. Steward Partners Investment Advisory LLC acquired a new stake in shares of Catalyst Pharmaceuticals in the fourth quarter worth $27,000. Farther Finance Advisors LLC lifted its position in shares of Catalyst Pharmaceuticals by 125.1% during the fourth quarter. Farther Finance Advisors LLC now owns 2,690 shares of the biopharmaceutical company’s stock worth $56,000 after purchasing an additional 1,495 shares during the last quarter. Wilmington Savings Fund Society FSB acquired a new position in shares of Catalyst Pharmaceuticals in the 4th quarter worth approximately $65,000. KBC Group NV increased its stake in Catalyst Pharmaceuticals by 48.8% during the fourth quarter. KBC Group NV now owns 4,699 shares of the biopharmaceutical company’s stock valued at $98,000 after purchasing an additional 1,542 shares during the last quarter. Finally, Thurston Springer Miller Herd & Titak Inc. bought a new position in Catalyst Pharmaceuticals in the fourth quarter worth about $134,000. Institutional investors and hedge funds own 79.22% of the company’s stock.

Catalyst Pharmaceuticals Price Performance

Shares of NASDAQ:CPRX opened at $22.74 on Thursday. Catalyst Pharmaceuticals, Inc. has a fifty-two week low of $14.47 and a fifty-two week high of $26.16. The business has a 50-day moving average of $22.68 and a two-hundred day moving average of $21.98. The stock has a market capitalization of $2.76 billion, a P/E ratio of 19.27, a P/E/G ratio of 3.31 and a beta of 0.79.

Analyst Upgrades and Downgrades

Several research firms recently commented on CPRX. StockNews.com upgraded Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Friday, February 28th. Robert W. Baird lifted their price target on Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the company an “outperform” rating in a research report on Monday, March 3rd. Stephens restated an “overweight” rating and issued a $33.00 price objective on shares of Catalyst Pharmaceuticals in a report on Thursday, February 27th. HC Wainwright reaffirmed a “buy” rating and set a $35.00 target price on shares of Catalyst Pharmaceuticals in a report on Friday, February 28th. Finally, Bank of America reissued a “buy” rating and issued a $30.00 price target on shares of Catalyst Pharmaceuticals in a report on Thursday, January 9th. Seven research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $32.29.

Insider Buying and Selling at Catalyst Pharmaceuticals

In other news, insider Gary Ingenito sold 44,904 shares of Catalyst Pharmaceuticals stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $22.09, for a total transaction of $991,929.36. Following the sale, the insider now directly owns 68,873 shares in the company, valued at approximately $1,521,404.57. The trade was a 39.47 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Brian Elsbernd sold 62,975 shares of Catalyst Pharmaceuticals stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $22.98, for a total value of $1,447,165.50. Following the transaction, the insider now directly owns 188,564 shares of the company’s stock, valued at approximately $4,333,200.72. The trade was a 25.04 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 11.00% of the company’s stock.

Catalyst Pharmaceuticals Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.